Eupraxia Pharmaceuticals, Inc. EPRX
TSX · Canada · Health Technology
CAD 11.19-1.80 (-13.86%)
Market closed· · CAD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · CAD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Eupraxia Pharmaceuticals (EPRX.TO), up 7.9% to a record high on last look, said on Wednesday updated
The highest dose group of EP-104GI (Cohort 9) demonstrated durability of symptom responses out to 52 weeks, with 66% of patients (2 of 3) maintaining clinical remission1The second highest dose group of EP-104GI (Cohort 8b) continued to show meaningful histologic reduction in inflammation and fibrosis with Stage –0.26 and Grade –0.27 in EoEHSS at 36 weeksThe Cohort 8b and Cohort 9 responses are consistent with clinical and histologic responses seen across all cohorts analyzed to date; in total, 9
On August 13, Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) released new data from its Phase 1b/2a RESOLVE trial showing that odynophagia, the medical term for painful swallowing, faded dramatically in patients treated with its lead drug candidate EP-104GI. In the highest-dose cohorts, moderate to severe odynophagia fell from 62% of patients at baseline to just 25% by […]
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.